Anti-CEACAM6 and TIM3 Antibody Combination for T-cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies face challenges in effectively targeting and eliminating cancer cells due to the immune system's limited capacity to react against autologous tumor cells, which is often hindered by immune checkpoints like CTLA-4, PD-1, and TIM-3.
Innovation Solution
The combination of an anti-CEACAM6 antibody, specifically TPP-3310, with an anti-TIM-3 antibody, such as cobolimab, MBG-453, or INCAGN-2390, to enhance T-cell activation and overcome immune checkpoint inhibition, thereby promoting a stronger antitumor response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint inhibitors (CTLA-4, PD-1, TIM-3) are used to enhance T-cell response against tumor cells, then T-cell activation is improved, but the immune system's capacity to react against autologous tumor cells remains limited due to multiple checkpoint mechanisms
Solution Approach 1:
The patent segments the immune checkpoint inhibition approach by targeting multiple distinct checkpoints (CTLA-4, PD-1, and TIM-3) with separate antibodies. This segmentation allows each antibody to address specific inhibitory pathways independently, collectively overcoming the complex multi-layered immune suppression that single agents cannot fully penetrate.
Solution Approach 2:
The patent employs a composite therapeutic approach by combining multiple immune checkpoint inhibitors in a single regimen. This composite strategy integrates the mechanisms of CTLA-4 blockade, PD-1 blockade, and TIM-3 blockade to create a synergistic effect that addresses the complexity of immune checkpoint inhibition more effectively than any single agent alone.
2Productivity
If single antibody therapy is used to target tumor cells, then treatment simplicity is maintained, but therapeutic efficacy is limited due to immune system's low capacity to react against autologous tumor cells
Solution Approach 1:
The patent merges three distinct immune checkpoint inhibitor antibodies (anti-CTLA-4, anti-PD-1, and anti-TIM-3) into a single combination therapy regimen. This merging strategy consolidates multiple mechanisms of action to achieve enhanced therapeutic efficacy against autologous tumor cells, overcoming the limitations of single antibody therapy while managing the complexity through coordinated administration.
3Reliability
If multiple immune checkpoints are targeted simultaneously, then T-cell unresponsiveness is overcome more effectively, but treatment complexity and potential side effects increase
Solution Approach 1:
The patent implements a feedback-controlled combination therapy approach where the simultaneous targeting of multiple checkpoints (CTLA-4, PD-1, TIM-3) is designed to restore balanced immune regulation. By addressing multiple inhibitory pathways, the therapy aims to achieve appropriate immune activation against tumor cells while maintaining control mechanisms that prevent harmful over-activation, thereby improving antitumor response strength without proportionally increasing side effects.
Data Source
AI summary
The present disclosure relates to combinations of at least two components, component A and component B, component A being anti-CEACAM6 antibody TPP-3310 and component B being an anti-TIM-3 antibody, preferentially cobolimab, MBG-453, BMS-986258, Sym-023, LY-3321367 or INCAGN-2390.